reversal of vitamin K antagonist deficiency and target level Dose for reversal depends on specific product and predose INR DDAVP Type I VWD or mild IV formulation—0.3 • Causes release of (desmopressin) hemophilia A (if mcg/kg in 50-mL VWF and FVIII patients known to NS by IV infusion from endothelial respond) over 30 (max cells dose 20 mcg) • Can exacerbate the Nasal spray thrombocytopenia formulation Stimate seen with type 2B (desmopressin VWD acetate) 1.5 mg/mL • Side effects: facial —metered dose flushing, pump delivers 0.1 headache, and, mL (150 mcg) per rarely, actuation for hypertension, patients ≥50 kg—2 hypotension, and sprays (1/nostril); water retention,